CytRx Corp $3.60

up +0.08


11/7/2014 04:25 PM  |  NASDAQ : CYTR  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get CYTR Trend Analysis - it has outperformed the S&P 500 by 33%

Partner Headlines

  1. Mid-Afternoon Market Update: Markets Turn Back As Meritor Hangs Onto Its ...

    Benzinga
  2. Mid-Day Market Update: Weight Watchers Shares Surge On Upbeat Results; ...

    Benzinga
  3. CytRx to Present Global Phase 2b Trial of Aldoxorubicin in Soft Tissue ...

    Benzinga
  4. Morning Market Movers

    Benzinga
  5. CytRx Reports Positive Results from Global Phase 2b Clinical Trial with ...

    Benzinga
  6. Morning Market Movers

    Benzinga
  7. Morning Market Movers

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Stocks Hitting 52-Week Highs

    Benzinga
  10. Morning Market Movers

    Benzinga
  11. A Small Cap That is Cashing In on ObamaCare

    Benzinga
  12. CytRx Announces Further Positive Clinical Data from Global Phase 2b Aldoxorubicin ...

    Benzinga
  13. CytRx Says Wins FDA Acceptance for Protocol of Phase 2 Aldoxorubicin in ...

    Benzinga
  14. Edison Investment Research Comments on CytRx Corporation Following Positive ...

    Benzinga
  15. Morning Market Losers

    Benzinga
  16. Benzinga's Top Pre-Market Losers

    Benzinga
  17. CytRx Prices 10M Share Offering at $2.25/Share

    Benzinga
  18. Stocks To Watch For October 9, 2013

    Benzinga
  19. CytRx Announces Proposed Public Offering of Common Stock

    Benzinga
  20. CytRx's Reports Aldoxorubicin Data Demonstrates Advantages over Doxorubicin ...

    Benzinga
  21. CytRx Corp. Reports Operating Results (10-Q)

    GuruFocus
  22. CytRx Closes Offering of 9.2M Shares

    Benzinga
  23. CytRx Announces Exercise of Underwriters' Over-Allotment Option

    Benzinga
  24. CytRx Prices 8M Share Offering at $2.50/Share

    Benzinga
  25. CytRx Announces Proposed Public Offering of Common Stock

    Benzinga
  26. CytRx's Aldoxorubicin Clinical Data Presented at the ESMO 2012 Congress

    Benzinga
  27. UPDATE: Rodman & Renshaw Initiates CytRx Corporation at Buy

    Benzinga
  28. From Earlier: CytRx Announces Favorable Results from Phase 1b/2 Clinical ...

    Benzinga
  29. Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN

    GuruFocus
  30. Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC

    GuruFocus
  31. Sickle Cell Knocks Out NFL Player. Can these Companies Help?

    Benzinga
Trading Center